2012
DOI: 10.1210/jc.2011-3135
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Implication of Highly Sensitive Detection of the BRAF V600E Mutation in Fine-Needle Aspirations of Thyroid Nodules: A Comparative Analysis of Three Molecular Assays in 4585 Consecutive Cases in a BRAF V600E Mutation-Prevalent Area

Abstract: Highly sensitive and specific molecular assays such as MEMO sequencing are optimal for detecting the BRAF mutations in thyroid FNAC because these techniques can detect PTC that might be missed by cytology or less sensitive molecular assays.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

7
96
1
1

Year Published

2013
2013
2021
2021

Publication Types

Select...
10

Relationship

4
6

Authors

Journals

citations
Cited by 95 publications
(107 citation statements)
references
References 31 publications
7
96
1
1
Order By: Relevance
“…Moreover, facilitating clinical outcome assessment for developing individualized treatment programs is necessary (Lee et al, 2012;Rossi et al, 2012;Nikiforov et al, 2013).…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, facilitating clinical outcome assessment for developing individualized treatment programs is necessary (Lee et al, 2012;Rossi et al, 2012;Nikiforov et al, 2013).…”
Section: Introductionmentioning
confidence: 99%
“…Detection of the mutation by either method was considered positive. DPO-PCR or mutant enrichment with 3′-modified oligonucleotides (MEMO) sequencing was conducted as previously described [17]. …”
Section: Methodsmentioning
confidence: 99%
“…org 5 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 15,18,19 The sensitivity and specificity for diagnosing BRAF V600E from FNA specimens vary depending on many factors, such as sample status 8 and molecular methods. 9,18 In addition, tumor size affects the detection rates of BRAF V600E mutations, according to the sensitivity of individual assays. 18 Herein, one case had a benign nodule with chronic lymphocytic thyroiditis on the basis of histological diagnosis; the BRAF V600E was detected by both Real-Q and MEMO sequencing and not by AS-PCR (Table 3).…”
Section: Evaluation Of Braf Assaymentioning
confidence: 99%